Rising India, Inc (OTCMKTS:RSII) Set to Hit the Ohio Medical Marijuana Scene


Rising India, Inc (OTCMKTS:RSII) is a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. The company is diversified into other areas, but we’re most interested in its current plans to take advantage of cannabis in the state of Ohio.


The passing of Ohio House Bill 523 officially made medical marijuana legal in September of 2016, but it is only now that the state is beginning issuance of medical marijuana licenses. RSII has been planning for this, and intends to become a player on the Ohio medical cannabis scene.


Rising India, Inc (OTCMKTS:RSII)’s Rising Bioscience subsidiary announced that its medical marijuana laboratory in Ohio is close to completion in line with the State of Ohio issuing medical marijuana licenses.


“Now that Ohio is beginning to issue licenses, we plan on being fully operational in our medical marijuana laboratory, which will focus on research, development, licensing and manufacturing of innovative products in the Cannabis space dedicated to serving patients with the highest standards,” stated COO Arthur Hall.


“We are also thrilled to announce that included in a line of medical cannabis products, the company is debuting Cannophen™, a revolutionary product we’ve been developing for some time now.  Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures.  This allows patients to take their medicine by swallowing a flavorless capsule, just like any other oral medication. We are also pleased to announce a new medical marijuana version of the TSW pain cream containing Cannabidiol (CBD).”

Hall added, “There has never been any proper way to dose with the above said methods.  We have developed Cannophen™ using the strictest quality and control standards and methods set forth in the pharmacy compounding industry using experienced chemists and veteran pharmacists. As well, Rising Biosciences is nearing completion on its FDA testing of the TSW (This Sh** Works) pain cream products. We’ve also had stellar feedback from those that received trial samples of the Clinical Strength Scar Peptide Serum and we now move into the next phase of production,” (Source: Globe Newswire)


We’re interested in RSII’s Ohio exploits primarily due to the fact that being relatively new to the list of places where medical marijuana has been legalized, we’re looking at an underdeveloped market in need of active players.


According to a 2017 report from New Frontier Data, it is estimated that by the year 2020, the legal cannabis market will create more than 250,000 jobs, more than the expected growth from manufacturing, utilities or even government jobs, according to the Bureau of Labor Statistics. Meanwhile, medical marijuana sales alone are expected to climb to nearly fifteen billion dollars in the same time frame. That’s why we want to ‘stock up’ on stocks in the space on our running watchlists. RSII is just the latest company to add to that growing list. We’ll be eager for more information on its Ohio lab, particularly with regard to expected production capacity. Keep it locked to Street Register for updates, and we’ll relay any important developments on RSII to you as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!



Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in RSII stock, short or long.